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Abstract 
 
Mammary gland development begins with the appearance of epithelial placodes that invaginate, 
sprout, and branch to form small arborized trees by birth. The second phase of ductal growth and 
branching is driven by the highly invasive structures called terminal end buds (TEBs) that form at 
ductal tips at the onset of puberty. Ectodysplasin (Eda), a tumor necrosis factor-like ligand, is 
essential for the development of skin appendages including the breast. In mice, Eda regulates 
mammary placode formation and branching morphogenesis, but the underlying molecular 
mechanisms are poorly understood. Fibroblast growth factor (Fgf) receptors have a recognized 
role in mammary ductal development and stem cell maintenance, but the ligands involved are ill-
defined. Here we report that Fgf20 is expressed in embryonic mammary glands and is regulated 
by the Eda pathway. Fgf20 deficiency does not impede mammary gland induction, but 
compromises mammary bud growth, as well as TEB formation, ductal outgrowth and branching 
during puberty. We further show loss of Fgf20 delays formation of Eda-induced supernumerary 
mammary buds and normalizes the embryonic and postnatal hyperbranching phenotype of Eda 
overexpressing mice. These findings identify a hitherto unknown function for Fgf20 in mammary 
budding and branching morphogenesis. 
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Introduction 
Mammalian fibroblast growth factors (Fgfs) constitute a family of 18 secreted polypeptide growth 
factors with diverse roles in multiple developmental processes1. Secreted Fgfs serve as ligands for 
single-pass transmembrane receptor tyrosine kinases (Fgfr1-4). With the exception of Fgfr4, 
alternative splicing of Fgfrs produces two isoforms (IIIb and IIIc isoforms) with different ligand 
binding specificities. In general, mesenchymal Fgfs encage epithelial IIIb receptor isoforms, 
whereas epithelial Fgfs signal to mesenchymal IIIc receptors2. Activation of any of these isoforms 
can trigger several signalling cascades including the RAS-MAPK, PI3K, STAT, and PLCγ 
pathways leading to various cellular responses in a context dependent manner. The fact that all 
Fgfs can bind to several Fgfrs, and vice versa, produces a high degree of redundancy within the 
system1.  
Mammary gland development proceeds via distinct stages: the hormone-independent embryonic 
and prepubertal morphogenesis, and the subsequent pubertal, pregnancy, lactation, and involution 
stages driven by hormonal cues3. In mice, mammary gland development commences at 
~embryonic day 11 (E11) with the sequential appearance of five pairs of mammary primordia 
called placodes4. Placodes are local epithelial thickenings that gradually invaginate to the 
underlying tissue to form buds, which from E12.5 onwards are surrounded by a specialized 
condensed mammary mesenchyme. Mammary buds grow relatively slowly in size until E15-E16 
when a primary sprout forms. The sprout invades the secondary mammary mesenchyme, the 
precursor of the fatty adult stroma, and branching morphogenesis begins. By birth (E19-E20), a 
small ductal tree with 10-15 branches has formed. Nipple sheath, as well as lumen formation also 
start at late embryogenesis4.  
Postnatal growth and branching is relatively slow until the onset of puberty, which begins at ~3 
week of age as a response to onset of ovarian steroid hormone production and is associated with 
remarkable morphological changes. Bulbous epithelial structures called terminal end buds (TEBs) 
form at the tips of mammary ducts and start invading into the fat pad3. This phase of rapid growth, 
which includes extensive ductal elongation, branching, and extracellular matrix (ECM) 
degradation, continues until the ductal network reaches the borders of the fat pad and the TEBs 
regress by the age of 10-12 weeks5. 
Mammary gland morphogenesis relies on sequential and reciprocal crosstalk between the 
epithelium and the underlying stroma and these tissue interactions guide all aspects of mammary 
gland development from induction to involution6. This crosstalk is mediated by conserved 
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signaling pathways, of which the Wnt and Fgf pathways are the most critical ones during the early 
stages of mammogenesis7,8. Loss of the Wnt signal mediator Lef1 leads to absence of placodes 2 
and 39, whereas epithelial overexpression of the soluble Wnt inhibitor Dkk1 prevents mammary 
placode formation altogether10. Deficiency in Fgf10 or its receptor Fgfr2b blocks induction of all 
mammary placodes except the fourth11. The initiation of bud outgrowth is triggered by epithelially 
expressed parathyroid hormone related peptide (PTHrP, a.k.a. parathyroid hormone like 
hormone): mice null for PTHrP or its mesenchymal receptor (Pth1r) display little to no bud 
sprouting12. Disruption of canonical Wnt signaling pathway components, such as Lrp6 results in 
stunted embryonic branching morphogenesis and underdeveloped fat pad13. Ductal growth and 
branching is also compromised, albeit to a lesser extent, in epidermal growth factor receptor 
(Egfr) null neonates14. 
Pubertal branching morphogenesis is regulated by systemic hormones, especially estradiol and 
growth hormone (GH)3,15. A critical factor induced by estrogen receptor α (Esr1) in the mammary 
epithelium is the Egf family member amphiregulin (Areg), which activates stromal Egfr 
signaling16-18. Accordingly, Areg and Esr1 knockout mice display a highly similar pubertal 
phenotype characterized by failure in TEB formation and ductal elongation18-20. GH signalling is 
essential in the mammary stroma where its effects are mediated by insulin-like growth factor 1 
(Igf-1), which in turn promotes epithelial cell proliferation and survival3. Both GH receptor and 
Igf-1 null mice exhibit greatly limited ductal outgrowth21,22. In addition, several other signaling 
molecules regulate ductal morphogenesis during puberty although their link to hormone signaling 
is less clear3,23.  
Also Fgf signaling plays an important role in mammary branching morphogenesis, as well as in 
maintaining homeostasis in the adult. Thus far, functional studies have focused on epithelial Fgfrs, 
in particular Fgfr2b, or their stromal ligands. The single pair (bud 4) of Fgf10 null mammary 
primordia sprouts, but shows either absent or very rudimentary ramifications11. Several studies 
have demonstrated the crucial role of Fgfr2 signaling in postnatal development including 
induction and maintenance of the TEBs, and in ability of mammary stem cells to repopulate the 
fat pad in transplantation assays24-27. Furthermore, conditional epithelial deletion of Fgfr1 leads to 
a ductal outgrowth phenotype, albeit transient, which is evident already at the onset of puberty26.  
Ectodysplasin-A1 (hereafter Eda), a member of the tumor necrosis factor (Tnf) superfamily has 
recently emerged as an important regulator of mammary gland development. Eda signaling is 
mediated via its receptor Edar and culminates in the activation of the transcription factor NF-κB28. 
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Eda pathway loss- and gain-of-function mouse models have been highly informative in 
elucidating the role of this pathway in mammary gland biology29-31. Eda is dispensable for 
mammary placode formation, yet Eda-overexpressing (K14-Eda) mice develop supernumerary 
mammary glands along and anterior to the milk line29,32,33. Deficiency in Eda, Edar, or NF-κB 
leads to smaller ductal trees, a phenotype that manifests from embryogenesis up to at least 6 
weeks of age. The converse is observed in Eda and Edar overexpressing mice30,34. In humans, 
inactivating mutations in the Eda pathway genes cause a syndrome characterized by defective 
development of several ectodermal organs including the breast35,36. In order to identify the 
transcriptional mediators of Eda/Edar/NF-κB, we performed microarray profiling of embryonic 
Eda null mammary buds after a 4-hour ex vivo exposure to control medium or recombinant Eda 
protein. This screen revealed several putative Eda target genes including Fgf2033, a member of the 
Fgf9 subfamily comprising of Fgf9, Fgf16, and Fgf201. Our previous studies have identified 
Fgf20 as an important downstream effector of Eda in developing hair follicles and teeth37-39. The 
present study unveiled an important role for Fgf20 in mammogenesis.  
Results 
Fgf20 is expressed in the embryonic mammary buds 
We have previously shown by microarray profiling that a short treatment with recombinant Eda 
protein upregulates the expression of Fgf17 and Fgf20 in the mammary buds of E13.5 Eda-/- 
embryos ex vivo33. Quantitative RT-PCR was used to validate these findings, as well as the 
expression of Fgf4 and Fgf9, two Fgf family members reported to be expressed in the mammary 
buds40 but not upregulated by Eda in the microarray. In line with the microarray results, after 4 
hours Eda-treatment, of these only Fgf17 and Fgf20 were upregulated 5.8-fold (p=0.042) and 3.8-
fold (p=0.019), respectively (Fig. 1a). However, analysis of the absolute mRNA quantity 
indicated that Fgf17 is expressed at a very low level, and thus the role of Fgf17 in mammary 
gland development was not analyzed further.  
In order to analyze expression of Fgf20 in embryonic mammary glands, we took advantage of the 
Fgf20-LacZ knock-in allele41 and performed X-gal staining on Fgf20LacZ/+ embryos between 
E10.5 and E18.5. Expression of Fgf20-LacZ was detected earliest at ~E11.25 in the mammary bud 
1 (data not shown), and at E11.5 in the buds 1 and 3 (Fig. 1b). At E13.5, Fgf20-LacZ expression 
was detected in all mammary buds (Fig. 1b) and accordingly, in situ hybridization with an Fgf20 
specific probe showed positive signal in wildtype embryos at the same stage (Fig. 1d). The Fgf20-
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LacZ expression was still relatively strong in the mammary buds at E15.5 (Fig. 1e) but was 
substantially downregulated at E16.5 (Fig. 1f,g). At E18.5, no expression of Fgf20-LacZ could be 
detected in the mammary glands by X-gal staining (Fig. 1h) or immunohistochemical staining 
with anti-β-galactosidase antibody, although expression in hair follicles was readily observed 
(Fig. S1a), as reported previously39. At postnatal stages, expression of Fgf20-LacZ was assessed 
by X-gal staining and anti-β-galactosidase antibody in mammary glands of 3-, 5- and 7-week-old 
Fgf20LacZ/+ and Fgf20LacZ/LacZ mice, and by qRT-PCR in samples from 3 different regions 
(proximal to nipple, middle, and distal to nipple) of 5-week old glands. No expression was 
detected in the postnatal mammary gland by any of the methods used (Supplementary Fig. S1).  
Eda levels influence the expression of Fgf20 in vivo 
The observation that Eda induced the expression of Fgf20 in the embryonic mammary buds ex 
vivo prompted us to study the influence of Eda on Fgf20 expression levels in vivo by analyzing 
the Fgf20-LacZ expression in Eda null and Eda-overexpressing (K14-Eda) embryos. In Eda-/- 
embryos there was a slight delay in the onset of Fgf20-LacZ expression at E11.5 followed by 
somewhat decreased signal at E12.5 compared to control or K14-Eda embryos (Fig. 2a,b). At 
E13.5-E14.5 expression in K14-Eda embryos appeared more intense (Fig. 2c,d), and at E15.5, 
Fgf20-LacZ expression levels correlated with the Eda status (Fig. 2e). Together, these data show 
that loss- and gain- of Eda influence Fgf20-LacZ expression, although modestly, yet clearly cues 
other than Eda have a more prominent impact on Fgf20 expression during embryogenesis. The 
Wnt pathway is the most likely positive regulator: the murine Fgf20 promoter is known to be 
highly responsive to β-catenin/Lef1 in promoter-reporter assays39. 
Absence of Fgf20 compromises mammary bud formation  
To elucidate the role of Fgf20 in mammary gland development, we first analyzed the expression 
of placode markers Wnt10b and PTHrP by RNA in situ hybridization in the mammary buds of 
Fgf20LacZ/+ and Fgf20LacZ/LacZ mice (Figs. 3, 4). At 46-48 somite stage (E11.5-E11.75) Wnt10b 
expression in the two genotypes was indistinguishable indicating that Fgf20 deficiency does not 
impede induction of mammary gland development (Fig. 3a). At E12.5, however, Wnt10b 
expression domain appeared smaller in Fgf20LacZ/LacZ embryos, the difference being most 
pronounced in bud 3 (Fig. 3b), which is the first bud to form11. Quantification of the Wnt10b 
expression domain confirmed a significant difference between the two genotypes (p=0.0007) (Fig. 
3b’). At E13.5, the same was observed with the PTHrP probe, or when Fgf20-LacZ expression 
was assessed by X-gal staining (Fig. 4). For a more detailed morphological analysis, EpCAM-
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stained mammary buds 3 were visualized by whole mount confocal microscopy in 3D (Fig. 3c,d). 
Quantification revealed that Fgf20LacZ/LacZ buds were substantially smaller than control buds at 
E13.5 (p=1.098E-13) and E15.5 (p=2.234E-6). In attempt to gain insights into the molecular 
mechanisms underlying the Fgf20LacZ/LacZ bud phenotype, we analyzed expression of Edar, Lef1, 
and Dkk4 at E12.5, and Lef1 protein at E13.5. No gross difference in Edar, or Lef1 expression 
was detected, but Dkk4 expression was somewhat reduced Fgf20LacZ/LacZ (Supplementary Fig. S2), 
as previously shown in hair placodes (Huh et al., 2013).  
The appearance of supernumerary mammary placodes between the endogenous buds 3 and 4 in 
K14-Eda mice has been shown at E12.5 by a number of Wnt pathway genes, and at E13.5 they 
are clearly visible by various mammary bud markers including PTHrP29,33,34. At E13.5 PTHrP 
was not detected between bud 3 and 4 in K14-Eda;Fgf20LacZ/LacZ embryos in contrast to K14-
Eda;Fgf20LacZ/+ embryos (Fig. 4a). Furthermore, stereomicroscopic inspection, as well as X-gal 
staining and subsequent analysis of histological sections suggested the absence of supernumerary 
mammary buds in the K14-Eda;Fgf20LacZ/LacZ mice at E13.5 (Fig. 4b). However, based on similar 
analyses, supernumerary mammary buds were detectable in K14-Eda;Fgf20LacZ/LacZ embryos 
slightly later, at ~E14.0 (Supplementary Fig. S3). Accordingly, supernumerary nipples were 
observed on the milk line and the neck region of pre- and post-pubertal K14-Eda;Fgf20LacZ/LacZ 
females (Supplementary Fig. S3). As previously reported for K14-Eda males34, also K14-
Eda;Fgf20LacZ/+ and K14-Eda;Fgf20LacZ/LacZ males had supernumerary nipples, and at least in the 
neck region, a ductal tree was readily observed in compound mutants (Supplementary Fig. S3). In 
conclusion, in the absence of Fgf20, all mammary buds formed, yet a clear reduction in bud size 
and a slight delay in appearance of supernumerary mammary buds in K14-Eda embryos was 
evident. 
Absence of Fgf20 delays ductal growth in puberty  
Macroscopic analysis of pubertal and adult Fgf20LacZ/LacZ females revealed the presence of the 
normal number of nipples. To examine the impact of Fgf20 deficiency on postnatal mammary 
morphogenesis, 4th mammary glands of 5-week-old WT and Fgf20 LacZ/LacZ were analyzed (Fig. 
5a-c). The number of the ductal ends was reduced by 35% (p=0.018) and TEBs by 51% (p=0.008) 
in Fgf20 LacZ/LacZ mice compared to WT controls (Fig. 5d,e). Also, the extent of ductal outgrowth 
(i.e. penetration to the fat pad) was significantly compromised (p=0.037) (Fig. 5f). These data 
clearly show that absence of Fgf20 greatly retards ductal outgrowth during puberty. The ductal 
characteristics were, however, quite variable among the Fgf20 LacZ/LacZ mice: often the ductal tree 
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was very rudimentary and barely contained any TEBs while in some mice the ductal tree was only 
modestly affected (Fig. 5a-c). Quantification of the maximum width of the five largest 
TEBs/ductal tips in each specimen confirmed a significant difference between Fgf20LacZ/LacZ and 
WT mice (p= 0.029) (Fig. 5g). Ki-67 expression analysis in TEBs evidenced a decrease in the 
number of proliferating cells in Fgf20 mutants (p= 0.0038) (Fig. 5h,i). 
No evidence for a systemic pubertal defect in Fgf20LacZ/LacZ females  
We detected Fgf20 expression only in the embryonic mammary glands (see above), yet 
Fgf20LacZ/LacZ mammary glands displayed a remarkable postnatal phenotype (Figs. 5 and 6). To 
assess whether the pubertal phenotype could be caused by a systemic defect due to the germline 
deletion of the Fgf20 gene, we analyzed various parameters in the mutant animals. We found no 
difference in the onset of puberty, nor in the weight of the animals at the onset of, or during 
puberty (at 3, 5, or 7 weeks of age), or the weight of ovaries and uteri (Supplementary Fig. S4). 
Yet, 18 % of 7-week-old Fgf20LacZ/LacZ females (n= 22) had completely closed vaginas, whereas a 
similar defect was not observed in WT mice (n= 9). These mice were not used for mammary 
gland analyses. The estrus cycles analyzed from vaginal smear cytology of WT and Fgf20LacZ/LacZ 
females were normal, and serum estradiol levels of the 7-week-old Fgf20LacZ/LacZ females in 
diestrus were similar to those of WT littermates (Supplementary Fig. S4). Finally, we performed 
mammary fat pad transplantations in which 1 mm3 pieces of adult Fgf20+/+ mammary glands were 
transplanted into the cleared fat pad of 3-to-4-week old WT or Fgf20LacZ/LacZ females and allowed 
to grow for 5 weeks before analysis. WT epithelium grew equally well in the fat pad of both 
recipients (Supplementary Fig. S4). Collectively, these data indicate that there is no gross 
systemic defect in Fgf20LacZ/LacZ females, which could explain the pubertal mammary phenotype. 
Absence of Fgf20 normalizes the hyperbranching phenotype of K14-Eda mice 
Our data showing that Fgf20 expression levels are modulated is regulated by Eda (Fig. 1) and loss 
of Fgf20 delays ductal growth at puberty (Fig. 5) prompted us to study the effects of Fg20 
deficiency on ductal branching at other developmental stages, as well as the crosstalk with the Eda 
pathway. At E18, the number of ductal ends in the mammary glands of Fgf20LacZ/LacZ embryos was 
similar to that of wildtype mice (p=0.638) (Fig. 6a,a’). However, mammary glands of 3-week-old 
Fgf20LacZ/LacZ mice contained somewhat lower number of ductal tips than those of WT controls 
(p=0.0321) (Fig. 6b,b’). At 7 weeks of age, the decrease in the ductal outgrowth and number of 
ductal ends in Fgf20LacZ/LacZ mice was prominent (p=0.0039 and p=0.0051, respectively) (Fig. 
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6c,c’,e), even more pronounced than at 5 weeks of age (Fig. 5d). However, at 12 weeks of age, the 
number of ductal ends was similar in both genotypes (p=0.363) (Fig. 6d,d’).  
Consistent with our previous results34, the number of ductal ends was significantly higher in K14-
Eda mice compared to WT controls at E18 (p=0.00009) and 3 weeks of age (p=0.0019) (Figs. 6 
a,a’,b,b’). The hyperbranching phenotype was apparent also at 7 (p=0.034) and 12 weeks of age 
(p=0.0004) (Fig. 6c,c’,d,d’). Surprisingly, even though Fgf20 null mammary glands did not 
display a growth phenotype at E18, the K14-Eda phenotype was greatly attenuated in 
Fgf20LacZ/LacZ background (p=0.0005) (Fig. 6a’). Also at later stages, loss of Fgf20 normalized the 
K14-Eda phenotype, although at 7 weeks of age, the difference did not reach statistical 
significance (p3wk=0.0046; p7wk=0.1521, p12wk=0.0011). These data identify Fgf20 as a critical 
mediator of Eda in mammary ductal growth and branching. 
At late puberty, the terminal end buds of Fgf20LacZ/LacZ mice are larger and more 
proliferative 
Since the growth delay of the Fgf20 mutants was most pronounced at 7 weeks of age, we analyzed 
the ducts and TEBs of Fgf20LacZ/LacZ and WT glands in more detail at this stage. The architecture 
of the ducts appeared normal based on all criteria used: histology, hormone receptor expression, 
the distribution of basal (K14) and luminal (K8) keratins, and the expression of basal cell marker 
α-SMA (Supplementary Fig. S5). Accordingly, FACS analysis did not show significant 
differences in the percentage of luminal (CD29loCD24+) or basal (CD29hi CD24+) cells between 
WT and the Fgf20LacZ/LacZ mice at 7 week of age, nor at 3 weeks when the growth phenotype was 
first evident (Supplementary Fig. S5). 
Analysis of TEBs, however, revealed that the epithelium appeared more cellular in Fgf20LacZ/LacZ 
mice compared to WT mice (Fig. 7a). TEB area, measured from the carmine alum whole mount 
images, was larger in Fgf20LacZ/LacZ mice at the same age (Fig. 7b). Quantification of Ki-67 and 
cleaved caspase-3 positive cells in TEBs revealed that the proportion of the proliferating cells was 
significantly higher in Fgf20LacZ/LacZ mice compared to WT controls (Fig. 7c,c’), but there was no 
difference in the proportion of apoptotic cells (Fig. 7d,d’). ERα and PR expression was 
indistinguishable between WT and Fgf20LacZ/LacZ TEBs (Fig. 7e,f). TEBs consist of a mass of 
luminal K8+ body cells surrounded by α-SMA+/p63+ cap cell layer. The expression patterns of 
body and cap cell markers were unchanged in 7-week old Fgf20LacZ/LacZ mice (Fig. 7g-i) indicating 
intact TEB architecture and cell identities. 
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Discussion 
In the current study, we have unveiled a role for Fgf20 in two stages of embryonic mammary 
gland development: budding and branching morphogenesis. Even though Fgf20 was dispensable 
for mammary placode induction, the buds were smaller in size. The molecular mechanism 
underlying the bud growth defect remain elusive. Furthermore, loss of Fgf20 delayed, but did not 
prevent, the formation of supernumerary mammary buds in K14-Eda embryos. Perinatally, Fgf20 
null mammary glands did not differ from the WT controls, yet the K14-Eda hyperbranching 
phenotype was greatly attenuated in Fgf20 null background. The most plausible explanation for 
these seemingly contradictory findings is redundancy of Fgf20 with other Fgf ligands, the most 
prominent candidate being Fgf9, a member of the same Fgf subfamily. Fgf9 is expressed in 
embryonic mammary glands40, shares similar biochemical properties with Fgf20 including 
receptor specificity1,2, and redundancy between these two Fgfs has already been demonstrated in 
developing teeth38, kidney42, and cochlea43. Other Fgfs reported to be expressed in mammary bud 
epithelium are Fgf4, Fgf8, and Fgf1740, which may further compensate for loss of Fgf20. 
 
Fgf signaling typically mediates crosstalk across tissue compartments1, but whether the effects of 
Fgf20 on mammary gland epithelium are direct, mediated by the stroma, or both, is currently 
unknown. Fgf20 preferentially, but not exclusively, activates the mesenchymally expressed IIIc 
receptors isoforms1,2. In the developing cochlea, epithelially expressed Fgf20 positively regulates 
epithelial progenitor proliferation via the mesenchyme, whereas intraepithelial Fgf20 signaling is 
essential for sensory cell differentiation41,43. In hair follicles, Fgf20 is dispensable for placode 
formation, but is necessary for condensation of the underlying mesenchymal cells, which in turn is 
required for further follicular downgrowth39. The target genes regulated by Fgf20 have remained 
elusive in all organs studied so far. 
 
We have previously shown that Eda regulates expression of Fgf20 in embryonic hair follicles and 
teeth where Fgf20 functions as one of the major downstream effectors of the Eda pathway38,39. 
Here, we identify Fgf20 as a mediator of Eda in the developing mammary glands: absence of 
Fgf20 delayed formation of supernumerary buds and normalized the hyperbranching mammary 
phenotype of K14-Eda mice, an effect maintained until adulthood. However, our data implicate 
the existence of other downstream targets of Eda besides Fgf20, since at E18 and at the onset of 
puberty, the ductal trees of Eda-null mice are more severely affected than those of Fgf20LacZ/LacZ 
mice34. Our earlier studies have identified several other Eda-induced factors that can enhance 
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branching morphogenesis such as PTHrP, Egfr ligands, and Wnt pathway agonists34. Hence, the 
Eda-null and K14-Eda branching phenotypes are likely the combinatorial result of changes in the 
expression level of multiple Eda target genes. 
 
Our data show that Fgf20 has a considerable impact on postnatal mammary morphogenesis since 
its absence led to defective TEB formation and delayed ductal invasion during puberty. However, 
the ductal growth defect was transient: the ductal trees caught up to the WT glands between 7 and 
12 weeks of age. We propose that this also explains the counterintuitive finding of increased cell 
proliferation in Fgf20LacZ/LacZ TEBs at 7 weeks of age. In WT glands, the percentage of 
proliferative cells in the TEBs decreases between 3 weeks of age and late puberty (7 weeks)26, 
whereas Fgf20LacZ/LacZ mammary glands begin their growth burst at 7 weeks of age. 
 
The embryonic phenotype and the subtle reduction in the number of branches in 3 weeks old 
Fgf20LacZ/LacZ mice implicates that the defect underlying the pubertal ductal phenotype may arise 
before puberty. We were unable to detect Fgf20 expression during puberty, not even by qRT-
PCR, a finding in line with a recent study assessing Fgf20 expression in mammary glands of 3, 5, 
and 10 week old mice27. Thus, it is plausible that Fgf20 deficiency during embryogenesis leads to 
qualitative changes in the mammary stem/progenitor cells that fully manifest only during puberty. 
Fittingly, a recent study implicated epithelial Fgfr1/2 signaling in proper mammary stem cell 
function during development26. However, we cannot exclude the possibility that Fgf20 is 
expressed during puberty in a rare cell population that escaped our analysis. To answer the 
question whether Fgf20 has a role in pubertal development independent of its embryonic function 
must await for the generation of a conditional Fgf20 mouse.  
  
The mammary phenotype of Fgf20LacZ/LacZ mice resembles the phenotypes generated by K14-Cre-
mediated deletion of Fgfr126 and MMTV-Cre-mediated (mosaic) deletion of Fgfr224, which both 
display compromised TEB formation, reduced number of branch points, and pubertal ductal 
outgrowth defect that normalizes in the adulthood. A complete failure in TEB maintenance is 
observed in mice inducibly overexpressing a transgene encoding a soluble form of Fgfr2b25. 
Interestingly, upon cessation of transgene expression 6 weeks after its induction, TEBs reform and 
branching is resumed. These data are suggestive of Fgfr signaling being essential for the 
functionality rather than survival of mammary stem/progenitor cells driving TEB formation and 
ductal invasion. 
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Pubertal ductal morphogenesis is a complex hormone regulated process, which involves cellular 
functions such as proliferation, apoptosis, migration, ECM degradation, and a tight interplay 
between epithelial and mesenchymal compartments6,15. A great number of genetically 
manipulated mice, and experiments using slowly-releasing protein pellets in vivo, are known to 
cause a pubertal mammary phenotype23,44. These studies show that loss of tissue integrity in TEBs 
readily leads to ductal outgrowth defects. However, this is unlikely the case in Fgf20LacZ/LacZ mice, 
as the expression pattern of body and cap cell markers was unaltered. Another important class of 
pubertal phenotypes is caused by loss- or gain-of-function of matrix remodeling enzymes such as 
matrix metalloproteinases (MMPs), which regulate ductal invasion and branching via their ability 
to sculpt the ECM45,46, and Fgfr1/2 stimulation has been shown to induce the expression of Mmp3 
and Mmp9 in several breast cancer and immortalized mammary epithelial cell lines47-51.   
 
In conclusion, our results identify a hitherto unknown function for Fgf20 in both embryonic and 
postnatal mammary gland morphogenesis. Our data suggest that compromised Fgf20 signaling 
during embryogenesis results in qualitative changes in TEBs that are thought to harbor the 
majority of stem cells driving branching morphogenesis during puberty52,53. To our knowledge, in 
addition to Fgf1011, Fgf20 is the only Fgf family member with a proven in vivo function in 
mammary gland development. Furthermore, we discovered Fgf20 as an important mediator of Eda 
in mammary gland budding and branching morphogenesis. Future studies should shed light on the 
molecular mechanisms downstream of Fgf20 in mammary gland morphogenesis.  
 
Materials and Methods 
Mice 
The generation and genotyping of Fgf20LacZ/LacZ, K14-Eda, and Eda-/- (Tabby; Jackson 
Laboratories, stock no 000314) mouse strains have been described previously41,54. Fgf20LacZ/LacZ 
and K14-Eda mice were maintained in the C57Bl/6 background (K14-Eda > 10 generations and 
Fgf20LacZ/LacZ >5 generations) and Eda-/- mice in the B6CBA background. Embryonic ages were 
defined based on the appearance of vaginal plug and external criteria including limb 
morphogenesis55. The sex of embryos older than E14 was defined by PCR with Sry-specific 
primers or anatomy, and only female mice were used for analysis unless otherwise stated. All 
mouse studies were approved and carried out in accordance with the guidelines of the Finnish 
national animal experimentation board. 
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Embryonic mammary bud cultures and quantitative RT-PCR 
The hanging drop culture method used for the embryonic mammary bud cultures has been 
described in detail previously33,34. Pooled (15-20 buds per pool) E13.5 Eda-/- mammary buds were 
treated with 250 ng/ml of Fc-Eda56 or control medium, RNA was extracted, cDNA synthesized, 
and qRT-PCR performed with the Light Xycler480 machine (Roche, Indianapolis, IA) as 
described33,34 using the following primers: 
Fgf4F 5’-CGAGGGACAGTCTTCTGGAG-3’, Fgf4R 5’-GTACGCGTAGGCTTCGTAGG-3’, 
Fgf9F 5’-GGGGAGCTGTATGGATCAGA-3’, Fgf9R 5’-CTTTGTCAGGGTCCACTGGT-3’ 
Fgf17F 5’-GACAGATACATTCGGCAGCA-3’, Fgf17R 5’-CTGGAAGGCCGTGTAGTTGT-3’, 
Fgf20F 5’-GTGCCAGGTCCAAAAGACAT-3’, Fgf20R 5’-GGAGAATGATCTTGCTTTGCTT-
3’. Dilution series of PCR products was used for quantifying the transcript numbers of genes of 
interest with the help of Lightcycler480 software. Ranbp1 (F 5’-
ACGCTGGAGGAAGATGAAGA-3’, and R 5’-TCATAAGAAGGCGGATGGTC-3’) or 
GAPDH (F 5’-CTCGTCCCGTAGACAAAATGG-3’ and  R 5’-AGATGGTGATGGGCTTCCC-
3’) were used as a reference genes.  
X-Gal and Carmine alum staining 
X-Gal staining for whole embryos (E10.5-E15.5) or abdominal skins of embryos (E16.5-E18) was 
performed according to a published protocol32 with an overnight incubation in the 1 mg/ml X-Gal 
substrate. For postnatal mammary glands, a modified X-Gal-staining method was used57. The X-
Gal stained samples were post-fixed with 4% PFA, dehydrated, embedded in paraffin and 
counterstained with nuclear fast red after sectioning. For quantification of mammary ductal ends, 
the 4th mammary glands and surrounding fat pads of E18, 3-, 5-, 7- and 12-week old mice were 
prepared, spread on slides and subjected to Carmine alum staining as previously described34. 
Quantification of ductal ends, TEBs, and the areas and maximum widths of TEBs was done 
manually from images with the help of Fiji ImageJ software. Ductal outgrowth was measured as 
the distance of the furthest grown ductal end from the center of the lymph node. 
 
In situ hybridization 
For whole mount in situ hybridization with digoxigenin-labeled RNA probes, E11.5-E13.75 
embryos were fixed in 4% PFA overnight at 4°C and dehydrated with rising methanol series. In 
situ hybridization was performed with inSituPro robot (Intavis AG) as previously published29,38 or 
manually using a similar protocol. The digoxigenin-labeled RNA probes for Wnt10b, Edar, Dkk4, 
Lef1, PTHrP and Fgf20 have been described earlier34; Fgf20 probe corresponded to the open 
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reading frame. BM Purple AP substrate Precipitating Solution (Boehringer Mannheim) was used 
for detection of digoxigenin-labeled RNA probes. Radioactive in situ hybridization was 
performed on paraffin sections using 35S-UTP labeled (Amersham) probe specific to Fgf20 as 
described38. 
Immunohistochemical stainings 
For immunohistochemical and hematoxylin-eosin stainings, the 4th mammary glands of WT and 
Fgf20LacZ/LacZ mice were dissected, spread on microscope slides, and fixed with 4% PFA overnight 
at 4°C. Alternatively, 13.5 trunks were dissected. The samples were dehydrated, embedded in 
paraffin, and 5µm sections were cut. Slides were deparaffinized by standard methods. In 
immunohistochemical stainings antigen retrieval was performed by heating the slides in 
microwave oven in TE buffer, pH 9.0 (keratin-8 (K8), keratin-14 (K14), progesterone receptor 
(PR) and estrogen receptor α (ERα) stainings), or in 10 mM sodium citrate buffer pH 6.0 (β-
Galactosidase, cleaved Caspase-3, Ki-67, α-smooth muscle actin (α-SMA), Lef1, and p63 
stainings). Primary and secondary antibodies used are listed in Supplementary information. 
Samples were imaged with a Zeiss Axio Imager M2 microscope equipped with an AxioCam HRc 
camera (Zeiss) and processed in Photoshop. 
Mammary bud area and volume quantification 
Wnt10b expression area was quantified manually from images with the help of Fiji ImageJ 
software. For whole-mount immunofluorescence staining E13.5 and E15.5 mouse embryos were 
fixed in 4% PFA at 4ºC overnight. After washing the samples with PBS for 3-4 hours, they were 
permeabilized with 0.3% TritonX-100 in PBS for 1-2 hours at room temperature, blocked (5% 
normal donkey serum, 0.5% BSA, and 0.3% TritonX-100 in PBS) for 1 h, and incubated at 4 °C 
with rat anti-mouse CD326 (EpCAM, BD Pharmingen, 552370, 1:1,000) and 10µg/ml Hoechst 
33258 (Molecular Probes/Invitrogen) in blocking buffer for 2 days. EpCAM was detected with an 
Alexa Fluor 647 –conjugated secondary antibody (Molecular Probes/Invitrogen). The ventral skin 
around mammary gland 2 and 3 was dissected and mounted with Vectashield (Vector 
Laboratories) and visualized using a Zeiss LSM700 laser scanning confocal microscope. For 
mammary placode and bud volume quantification, the area of mammary primordium was outlined 
manually based on EpCAM expression and bud morphology. Surface rendering and volume 
quantification were performed with Imaris 8.3 software (Bitplane). 
Mammary cell preparation, cell labelling, and flow cytometry 
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Single cell suspension of mammary gland was prepared according to the protocol modified from 
Shackleton et al., 200658. Briefly, the 4th mammary glands were cut into small pieces after 
removal of the lymph node. The tissues were digested in a mixture of 5 ml collagenase I buffer 
(10% FBS, 100 mg/ml streptomycin, 100 U/ml penicillin, 300 U/ml collagenase I (ThermoFisher) 
and 100U/ml hyaluronidase (Sigma) in DMEM/F12 (1:1) medium for 1-2 hours at 37ºC with 
moderate shaking. The cell suspension was washed in PBS and digested further in 0.25% trypsin-
EDTA for 5-10 minutes. The red blood cells were removed by incubation in red blood cell lysing 
buffer (Biolegend) on ice for 5 minutes. The single cell suspension was passed through 40 µm cell 
strainer (BD Bioscience) before stained with the mixture of antibodies on ice for 30 minutes. 
After washing in PBS, the dead cells were labeled with Fixable Viability Dye eFluor 780 
(eBioscience) for 30 minutes on ice. Flow cytometry was carried out by BD LSR II, and data 
analysis was done by Flowjo. The following antibodies were used: CD45-PE (Biolegend, 103106, 
1:200), CD31-PE (Biolegend, 102507, 1:200), TER119-PE (Biolegend, 116207, 1:200) CD24-
PeCy7 (Biolegend, 101822, 1:200) and CD29-APC (eBioscience, 17-0291-82, 1:200).  
Monitoring the onset of puberty, estrous phase, and measurement of sex steroids 
Onset of puberty was assessed by monitoring the vaginal opening (VO) by visual examination of 
vulva59 every morning 5 days/week (Mon-Fri) starting at the age of 18 days until the appearance 
of VO. In case of VO occuring during the weekend, the earliest, latest, and average times of VO 
were defined and separate comparisons of Fgf20LacZ/LacZ and WT mice were done using average 
VO time as well as extreme VO times (eg. VOWTlatest vs. VOFgf20LacZ/LacZ earliest and vice versa). 
Estrus phase was defined by examining the vaginal cytology collected by vaginal lavage with PBS 
using a small pipet and stained by crystal blue as previously described60. For monitoring the 
regularity of estrus cycles, 7-week and 12-week-old Fgf20LacZ/LacZ and WT females were examined 
5 days/week in the mornings for at least two weeks. 
Estradiol levels were measured from serum of 7-week-old mice in diestrus by highly sensitive gas 
chromatography-tandem mass spectrometry61. In case of obtaining zero value from the 
measurement (n=3 in both WT and Fgf20LacZ/LacZ), value equal to ½ LLOD (lower limit of 
detection) of estradiol (0.15 pg/ml) was used for the sample61. Mice were sacrificed, blood 
samples were immediately taken by heart puncture and kept overnight at 4°C. Mammary glands 
were used for FACS analysis and immunohistochemistry and uterus and ovaries were carefully 
dissected and weighted. Serum was dissociated the following day by centrifugation in at 3000 rpm 
at 4°C. Minimum of 250µl of serum was required for mass spectrometry analysis. 
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Mammary fat pad transplantations 
For mammary fat pad transplantations, 3-4 week old WT (n=6) and Fgf20 LacZ/LacZ (n=5) recipient 
females were anesthetized and the fat pad of left 4th mammary gland was cleared until the lymph 
node as described62. ~1 mm3 pieces of adult (12-13-week-old) WT donor (n=4) mammary glands 
were transplanted into cleared fat pads. Five weeks later transplanted mammary glands were 
collected, stained by Carmine alum, and ductal ends quantified. 
Statistical analysis 
P-values were calculated with unpaired t-test assuming unequal variances unless otherwise stated. 
Data availability 
The datasets generated during the current study are available from the corresponding author on 
reasonable request. 
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Figure 1. Fgf20 is induced by Eda and is expressed in embryonic mammary glands. (a) qRT-
PCR analysis of Fgf4 (n=4), Fgf 9 (n=4), Fgf17 (n=6) and Fgf20 (n=7) expression in E13.5 Eda-/- 
mammary buds after 4h treatment with Eda protein ex vivo. Values represent mean ±SD. (b,c) X-
gal-stained whole mounts of Fgf20LacZ/+ embryos at E11.5 (b) and E13.5 (c) showing positive 
staining in the developing mammary buds (numbered). (d) In situ hybridization of a WT embryo 
with an Fgf20 specific probe at E13.5. (e,f) X-Gal stained whole mount of E15.5 whole embryo 
(e) and dissected skin of E16.5 embryo (f) showing staining in the developing mammary buds 
(numbered) and hair follicles. (g,h) Representative figures of histological sections of X-Gal whole 
mount-stained mammary glands of Fgf20LacZ/+ embryos at E16.5 (g) and E18.5 (h). *, p<0.05. At 
least two litters of Fgf20LacZ/+ embryos per stage were analyzed. *, p<0.05. Scale bars 500 µm (b-
e), 100 µm (f-h). mb, mammary bud. 
Figure 2. The influence of loss (Eda-/-) and gain of Eda (K14-Eda) on the expression of 
Fgf20-LacZ in embryonic mammary glands. (a, b) Whole-mount X-Gal staining of Eda-/-
;Fgf20LacZ/+; Eda+/+;Fgf20LacZ/+, and K14-Eda;Fgf20LacZ/+ embryos at E11.5 and E12.5. (c-e) 
Histological sections of whole mount X-Gal stained mammary buds at E13.5 (mb2), E14.5 (mb2), 
and E15.5 (mb3). Scale bars 500 µm (a,b), 100 µm (c-e). 
Figure 3. Fgf20 deficiency does not impede placode induction but compromises bud growth. 
(a) Expression of Wnt10b at somite stage 46-48 (Fgf20LacZ/+, n=7; Fgf20LacZ/LacZ, n=7) and (b) 
E12.5 (Fgf20LacZ/+, n=6; Fgf20LacZ/LacZ, n=6), and (b’) quantification of Wnt10b expression area at 
E12.5. (d,e) 3D images and volume quantifications of EpCAM-stained mammary bud 3 at E13.5 
(Fgf20LacZ/+, n=24; Fgf20LacZ/LacZ, n=28), and E15.5 (Fgf20LacZ/+, n=8; Fgf20LacZ/LacZ, n=13). The 
bud contours were outlined manually (purple) for volume quantification. ***, p<0.001; ****, 
p<0.0001. Scale bars 1000 µm (a-b), 100 µm (c, d). 
Figure 4. Fgf20 deficiency delays induction of supernumerary buds in K14-Eda mice. 
(a) Expression of PTHrP at E13.5 (Fgf20LacZ/+, n=4; Fgf20LacZ/LacZ, n=4; K14-Eda;Fgf20LacZ/+, 
n=7; K14-Eda;Fgf20LacZ/LacZ, n=5), and (b) X-gal staining of Fgf20-LacZ at E13.5 (Fgf20LacZ/+, 
n=4; Fgf20LacZ/LacZ, n=6; K14-Eda;Fgf20LacZ/+, n=11; K14-Eda;Fgf20LacZ/LacZ, n=8). 
Supernumerary placodes (stars) were detected between buds 3 and 4 in K14-Eda;Fgf20LacZ/+ 
embryos at E13.5, but not in K14-Eda;Fgf20LacZ/LacZ embryos. 
Figure 5. Fgf20 deficiency compromises TEB formation and ductal invasion. (a-c) Carmine 
alum stained ductal trees of the 4th mammary gland (a,b) and histology of TEBs (c) of WT and 
Fgf20LacZ/LacZ mice at 5 weeks of age. (d-g) Quantification of the ductal ends (d), TEBs (e), ductal 
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outgrowth (measured as the distance of furthest grown ductal end from the center of the lymph 
node) (f), and width of five biggest ductal ends in each gland (f) in WT (n=6) and Fgf20LacZ/LacZ 
(n=10) mice.  (h, i) Immunohistochemical staining and quantification of Ki-67 -positive cells in 
TEBs of WT (n=4) and Fgf20LacZ/LacZ (n=3) mice. Total number of TEBs analyzed was n=15 
(WT), n=9 (Fgf20LacZ/LacZ). Bars show mean ±SD. *, p<0.05; **, p<0.01. Scale bars 1 mm (a,b), 
100µm (c, h). 
Figure 6. Loss of Fgf20 attenuates the K14-Eda hyperbranching phenotype. (a-d) Carmine 
alum stained 4th mammary gland of WT, Fgf20LacZ/LacZ, K14-Eda, and K14-Eda;Fgf20LacZ/LacZ 
mice at E18 (a), 3 weeks (b), 7 weeks (c), and 12 weeks of age (d). (a’-d’) Quantification of the 
total number of end ducts (a’,b’) or end ducts past the lymph node (c’,d’) in 4th mammary gland .  
Number of glands analyzed were: WT (nE18=5, n3wk=18, n7wk=12, n12wk=15)  Fgf20LacZ/LacZ (nE18=8, 
n3wk=16, n7wk=28, n12wk=5), K14-Eda (nE18=7, n3wk=8 , n7wk=7, n12wk=13) and K14-Eda;Fgf20LacZ/LacZ 
(nE18=6, n3wk=8 , n7wk=9, n12wk=10) (e) Ductal outgrowth (mm) measured from center of the lymph 
node in Fgf20+/+ (nglands=7) and Fgf20LacZ/LacZ (nglands=23). Data are shown as mean ±SD. *** p< 
0.001; ** p< 0.01; * p< 0.05; NS, not significant. Scale bars 1 mm. 
Figure 7. Analysis of terminal end buds of Fgf20LacZ/LacZ mice at 7 weeks of age. (a) 
Hematoxylin Eosin -stained sections of WT and Fgf20LacZ/LacZ TEBs. (b) Quantification of TEB 
area from Carmine alum stained mammary glands of WT (n=9) and Fgf20LacZ/LacZ (n=12) mice. (c, 
c’) Immunohistochemical staining and quantification of Ki-67 –positive cells in TEBs of WT 
(n=4) and Fgf20LacZ/LacZ (n=5) mice. Total number of TEBs analyzed was n=26 (WT), n=30 
(Fgf20LacZ/LacZ). (d,d’) Immunohistochemical staining and quantification of cleaved caspase-3 –
positive cells in WT (n=4) and Fgf20LacZ/LacZ mice (n=4). Total number of TEBs analyzed was 
n=34 (WT), n=29 (Fgf20LacZ/LacZ).  (e-i) Immunohistochemical staining of ERα (e), PR (f), K8 and 
K14 (g), SMAα (h), and p63 (i) in the TEBs of WT and Fgf20LacZ/LacZ mice. Minimum of 4 mice 
per genotype were analyzed. Values represent mean ±SD. ** p< 0.01; * p< 0.05; NS, not 
significant. Scale bars 100 µm. 







